Skip to main content
Premium Trial:

Request an Annual Quote

Shimadzu and Proteome Systems Expand North American Marketing Alliance

NEW YORK, March 2 (GenomeWeb News) - Shimadzu Scientific Instruments and Proteome Systems have expanded a broad alliance that they began in 2000, the companies said today.

Under the terms of the extended agreement, Proteome Systems and Shimadzu will co-market the Xcise robotic gel processing platform and ChIP (Chemical Inkjet Printer) technologies, which the companies jointly developed. Previously, Shimadzu was the sole distributor of these products.

In addition, Proteome Systems will expand its presence on the West Coast by showcasing some of its equipment at Shimadzu's Pleasanton, Calif., demonstration facilities. The companies already demonstrate their integrated proteomics technologies at Proteome Systems' Woburn, Mass., facility.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.